abstract
1. Prospect: grasp manufacturing and welcome innovation
Pharmaceutical policy: the three links of pharmaceutical policy are gradually improved and accelerated, and the policy expectation is not passivated;
Industry operation: the accumulated balance of medical insurance is accelerated to be incorporated into the trend of innovative drugs, so as to lay the foundation for sustainable growth of the industry;
Historical recovery: policy expectations are disturbed, the performance of “core assets” is flat in 2021, and “manufacturing and innovation” in 2022.
2. Choice: transition period, new kinetic energy
China Meheco Group Co.Ltd(600056) with the deepening of policies and entering the transition period, the old “core assets” are facing more inevitable transformation pressure. The key is to establish industrial chain thinking, optimize manufacturing and innovation. Key recommendation: Companies in such subdivided fields as characteristic API, upstream R & D and cdmo.
Manufacturing: API, cdmo, etc; Recommend Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) , Apeloa Pharmaceutical Co.Ltd(000739) , Wuxi Apptec Co.Ltd(603259) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Porton Pharma Solutions Ltd(300363) , Hainan Poly Pharm.Co.Ltd(300630) , etc;
Upstream: pharmaceutical equipment, reagents, consumables and other fields; Recommend Sensong international, Tofflon Science And Technology Group Co.Ltd(300171) , Shanghai Titan Scientific Co.Ltd(688133) , Shanghai Aladdin Biochemical Technology Co.Ltd(688179) , Jenkem Technology Co.Ltd(688356) and pay attention to Qingdao Haier Biomedical Co.Ltd(688139) , Zhejiangtailin Bioengineering Co.Ltd(300813) , Truking Technology Limited(300358) , Iray Technology Company Limited(688301) , Qingdao Novelbeam Technology Co.Ltd(688677) ;
Innovation: International equipment and drug companies; Recommend Micro-Tech (Nanjing) Co.Ltd(688029) , pay attention to Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , minimally invasive medicine, Beijing Balance Medical Technology Co.Ltd(688198) , Baiji Shenzhou, Xinda biology, Shanghai Junshi Biosciences Co.Ltd(688180) , kangfang biology, etc;
Others: consumer property, medical services, innovative supporting industry companies; Recommend Hangzhou Tigermed Consulting Co.Ltd(300347) , Joinn Laboratories (China) Co.Ltd(603127) , and focus on Chongqing Zhifei Biological Products Co.Ltd(300122) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , Shenzhen Kangtai Biological Products Co.Ltd(300601) , Aier Eye Hospital Group Co.Ltd(300015) , Topchoice Medical Co.Inc(600763) , Hubei Jumpcan Pharmaceutical Co.Ltd(600566) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) .
Risk statement
Risk of industrial policy change
Trade friction brings the risk of order volatility in export-oriented industries
Risk of short-term trend uncertainty caused by event impact
